“Paul Thau, Cecile Meunier and Dr. Charlie Ware will each focus on a different area of licensing and product expansion for Greyson,” said the company’s CEO Harvey Tauman.
“We are confident in their abilities to reach the largest and most influential organizations in these industries and to offer their expertise in securing licensing opportunities for Trilexon.”
Building on years of industry experience
Paul Thau will serve as research and development consultant for the company and comes with 22 years of experience at Cosmair L’Oreal USA, while Cecile Meunier will serve as marketing consultant and Dr. Ware will serve as research and development consultant.
Meunier has cosmetics industry experience as a brand and product manager, working with brands such as Vichy and Boots, whereas Dr. Ware has experience in the fields of homeopathy and oriental medicine.
Speaking of the appointments, Tauman said: “These three consultants with an abundance of experience in the health and beauty industries in product development will be assisting us in licensing Trilexon, our breakthrough delivery system for topical applications.”
Improving performance for a range of formulations
Trilexon is a new skin care delivery system that is designed with the aim of improving the effectiveness of a broad range of formulations.
The system has been developed to deliver key ingredients to the appropriate areas of the skin and the skin’s dermal layers through what the company terms “messengers“.
Ultimately the delivery system provides a more targeted result, achieving higher effectiveness and more noticeable results, the company says.
Trilexon key ingredient for anti-aging range
Greyson formulators say they have already established the delivery system’s effectiveness by combining it in three products aimed at the anti-aging market and all bearing the Trilexon brand name.
The products were launched last year onto the market in the US and include a Line Smoother, Eye Cream and a Night Cream, which are being marketed as a tri-pack combination anti-aging treatment.
By combining a time delivery mechanism, the company believes that there is currently no comparable delivery system on the market and is hoping that this factor will help to give the brand a unique selling point.